{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:35:15Z","timestamp":1791135315240,"version":"4.1.0"},"reference-count":41,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The use of microbicides is a promising approach for the prevention of HIV-1 transmission. Unfortunately, various candidates failed in clinical trials. In some cases, the candidate microbicide even resulted in enhanced virus transmission. Therefore, there is an urgent need to develop more predictive preclinical strategies to anticipate the\n            <jats:italic>in vivo<\/jats:italic>\n            efficiency\/toxicity rate, including\n            <jats:italic>in vitro<\/jats:italic>\n            assays that evaluate effects on epithelial integrity and inflammation. The present study aims to identify potential safety issues concerning the use of microbicides and excipients commonly used in vaginal microbicide preparations. The toxicities of various active pharmaceutical ingredients (APIs; TMC-120, UC-781, tenofovir [PMPA], PRO-2000, and glycerol monolaurate [GML]) and excipients (preservatives, cosolvents, surfactants, and cyclodextrins) were evaluated using an\n            <jats:italic>in vitro<\/jats:italic>\n            dual-chamber model and uterine cervical explants. Epithelial viability and permeation of fluorescent virus-sized beads, as well as induction of interleukin-8 (IL-8; as a sensitive marker of an inflammatory response), were assessed. Surprisingly, cell viability and epithelial layer integrity were compromised by most excipients at concentrations near the typical concentration used in vaginal gels, and a significant increase in the production of IL-8 was observed at subtoxic concentrations. Within the APIs, TMC-120, UC-781, and PMPA showed higher selectivity indices than PRO-2000 and GML. In conclusion, identification of safety issues concerning the use of pharmaceutical excipients could help to formulate less toxic vaginal microbicide preparations.\n          <\/jats:p>","DOI":"10.1128\/aac.00456-10","type":"journal-article","created":{"date-parts":[[2010,10,5]],"date-time":"2010-10-05T04:24:45Z","timestamp":1286252685000},"page":"5105-5114","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":60,"title":["<i>In Vitro<\/i>\n            Evaluation of Viability, Integrity, and Inflammation in Genital Epithelia upon Exposure to Pharmaceutical Excipients and Candidate Microbicides"],"prefix":"10.1128","volume":"54","author":[{"given":"Youssef","family":"Gali","sequence":"first","affiliation":[{"name":"Virology Unit, Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium"},{"name":"Department of Biomedical Sciences, Faculty of Pharmacology, Biomedical, and Veterinary Sciences, University of Antwerpen, Antwerp, and Faculty of Medicine and Pharmacology, University of Brussels, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Delezay","sequence":"additional","affiliation":[{"name":"Groupe Immunite\u0301 des Muqueuses et Agents Pathoge\u0300nes, EA3064, Universite\u0301 de Lyon, Lyon, and CHU of Saint-Etienne, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Brouwers","sequence":"additional","affiliation":[{"name":"Laboratory for Pharmacotechnology and Biopharmacy, Katholieke Universiteit Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noura","family":"Addad","sequence":"additional","affiliation":[{"name":"Groupe Immunite\u0301 des Muqueuses et Agents Pathoge\u0300nes, EA3064, Universite\u0301 de Lyon, Lyon, and CHU of Saint-Etienne, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Augustijns","sequence":"additional","affiliation":[{"name":"Laboratory for Pharmacotechnology and Biopharmacy, Katholieke Universiteit Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bourlet","sequence":"additional","affiliation":[{"name":"Groupe Immunite\u0301 des Muqueuses et Agents Pathoge\u0300nes, EA3064, Universite\u0301 de Lyon, Lyon, and CHU of Saint-Etienne, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Hamzeh-Cognasse","sequence":"additional","affiliation":[{"name":"Groupe Immunite\u0301 des Muqueuses et Agents Pathoge\u0300nes, EA3064, Universite\u0301 de Lyon, Lyon, and CHU of Saint-Etienne, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K.","family":"Arie\u0308n","sequence":"additional","affiliation":[{"name":"Virology Unit, Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pozzetto","sequence":"additional","affiliation":[{"name":"Groupe Immunite\u0301 des Muqueuses et Agents Pathoge\u0300nes, EA3064, Universite\u0301 de Lyon, Lyon, and CHU of Saint-Etienne, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Vanham","sequence":"additional","affiliation":[{"name":"Virology Unit, Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium"},{"name":"Department of Biomedical Sciences, Faculty of Pharmacology, Biomedical, and Veterinary Sciences, University of Antwerpen, Antwerp, and Faculty of Medicine and Pharmacology, University of Brussels, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004180050172"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.61.4.962-971.1987"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.713-723.2006"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(05)70143-4"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01129-06"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70254-8"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.10.3834-3844.2004"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199601001-00007"},{"key":"e_1_3_2_10_2","unstructured":"Inactive ingredient search for approved drug products"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001474"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod.104.029603"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/322047"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01156-08"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-3-46"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2010.01.018"},{"key":"e_1_3_2_17_2","first-page":"14","volume":"25","year":"2001","unstructured":"Garg, S., K. R. Tambwekar, K. Vermani, A. Garg, C. L. Kaul, and L. J. D. Zaneveld. 2001. Compendium of pharmaceutical excipients for vaginal formulations. Pharm. Technol.25:14-24.","journal-title":"Pharm. Technol."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/108729103322277402"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.6.1611"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.12.5577-5586.2000"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003784"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000159671.25950.74"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.7.2292-2298.2002"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(72)90861-7"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2004.04.010"},{"key":"e_1_3_2_26_2","first-page":"273","volume":"4","year":"1995","unstructured":"Mayer, K. H., and D. J. Anderson. 1995. Heterosexual HIV transmission. Infect. Agents Dis.4:273-284.","journal-title":"Infect. Agents Dis."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200302140-00005"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/600867"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/164.3.588"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b5538"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009310"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00989-08"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61842-5"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00707-07"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01627-07"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11079-8"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2007.07.004"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318159d5a8"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.10.010"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1461-5347(00)00296-0"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020142"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200108170-00014"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00456-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00456-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:23:24Z","timestamp":1645475004000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00456-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1128\/AAC.00456-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.00456-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"2010-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-09-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}